Cargando…

Bioinformatic Analysis of Prognostic Value of SNTG2 with Immune Implications in Lung Adenocarcinoma

BACKGROUND: Lung cancer is the most morbid and fatal cancer in the world, and nearly 85% of lung cancer is non-small cell lung cancer (NSCLC). Besides traditional chemotherapies, molecular targeted therapies and immunotherapies are increasing rapidly, but the treatment is still unsatisfactory. The s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jian, Wen, Yang, Chen, Xiangtian, Guo, Linlang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148212/
https://www.ncbi.nlm.nih.gov/pubmed/35637702
http://dx.doi.org/10.2147/IJGM.S355393
_version_ 1784716995567026176
author Zhou, Jian
Wen, Yang
Chen, Xiangtian
Guo, Linlang
author_facet Zhou, Jian
Wen, Yang
Chen, Xiangtian
Guo, Linlang
author_sort Zhou, Jian
collection PubMed
description BACKGROUND: Lung cancer is the most morbid and fatal cancer in the world, and nearly 85% of lung cancer is non-small cell lung cancer (NSCLC). Besides traditional chemotherapies, molecular targeted therapies and immunotherapies are increasing rapidly, but the treatment is still unsatisfactory. The study is to identify a new diagnostic and prognostic biomarker. METHODS: Data including mRNA expression and clinical information of lung adenocarcinoma (LUAD) patients were downloaded from The Cancer Genome Atlas (TCGA) database. Receiver operating characteristic (ROC) curve was constructed to assess the diagnostic value of syntrophin-γ2 (SNTG2) expression and Kaplan–Meier (KM) survival curves were used to compare the survival disparities. The protein–protein interaction (PPI) network was analysed by Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) and the connections between SNTG2 and immune cell infiltration were found with Tumor Immunoassay Resource (TIMER). Genetic mutation in SNTG2 and its association with overall survival (OS) were evaluated by cBioPortal. The relationship between SNTG2 and methylation and its association with overall survival were evaluated by MethSurv. Chi square and Mann–Whitney tests were used for statistical analyses. Xiantao Academic Online Website was used for online analysis. RESULTS: Our results revealed that SNTG2 mRNA expression was lower in LUAD tissues than in both adjacent and non-adjacent normal tissues and low SNTG2 mRNA expression was verified to be correlated with histological grade, clinical stage, first therapy outcome and poor overall survival of LUAD. Next, ROC curve revealed diagnostic and prognostic value of SNTG2 for LUAD patients. Moreover, SNTG2 presented correlation with immune cell infiltration and immune checkpoints. Then, we revealed CC chemokine ligand 14 (CCL14), a co-expression gene with SNTG2, which has consistent influence with SNTG2. Furthermore, hypomethylation was found to be associated with high SNTG2 expression. CONCLUSION: We revealed a potential diagnostic and prognostic indicator in LUAD and analyzed its influence on immunotherapy.
format Online
Article
Text
id pubmed-9148212
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-91482122022-05-29 Bioinformatic Analysis of Prognostic Value of SNTG2 with Immune Implications in Lung Adenocarcinoma Zhou, Jian Wen, Yang Chen, Xiangtian Guo, Linlang Int J Gen Med Original Research BACKGROUND: Lung cancer is the most morbid and fatal cancer in the world, and nearly 85% of lung cancer is non-small cell lung cancer (NSCLC). Besides traditional chemotherapies, molecular targeted therapies and immunotherapies are increasing rapidly, but the treatment is still unsatisfactory. The study is to identify a new diagnostic and prognostic biomarker. METHODS: Data including mRNA expression and clinical information of lung adenocarcinoma (LUAD) patients were downloaded from The Cancer Genome Atlas (TCGA) database. Receiver operating characteristic (ROC) curve was constructed to assess the diagnostic value of syntrophin-γ2 (SNTG2) expression and Kaplan–Meier (KM) survival curves were used to compare the survival disparities. The protein–protein interaction (PPI) network was analysed by Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) and the connections between SNTG2 and immune cell infiltration were found with Tumor Immunoassay Resource (TIMER). Genetic mutation in SNTG2 and its association with overall survival (OS) were evaluated by cBioPortal. The relationship between SNTG2 and methylation and its association with overall survival were evaluated by MethSurv. Chi square and Mann–Whitney tests were used for statistical analyses. Xiantao Academic Online Website was used for online analysis. RESULTS: Our results revealed that SNTG2 mRNA expression was lower in LUAD tissues than in both adjacent and non-adjacent normal tissues and low SNTG2 mRNA expression was verified to be correlated with histological grade, clinical stage, first therapy outcome and poor overall survival of LUAD. Next, ROC curve revealed diagnostic and prognostic value of SNTG2 for LUAD patients. Moreover, SNTG2 presented correlation with immune cell infiltration and immune checkpoints. Then, we revealed CC chemokine ligand 14 (CCL14), a co-expression gene with SNTG2, which has consistent influence with SNTG2. Furthermore, hypomethylation was found to be associated with high SNTG2 expression. CONCLUSION: We revealed a potential diagnostic and prognostic indicator in LUAD and analyzed its influence on immunotherapy. Dove 2022-05-24 /pmc/articles/PMC9148212/ /pubmed/35637702 http://dx.doi.org/10.2147/IJGM.S355393 Text en © 2022 Zhou et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhou, Jian
Wen, Yang
Chen, Xiangtian
Guo, Linlang
Bioinformatic Analysis of Prognostic Value of SNTG2 with Immune Implications in Lung Adenocarcinoma
title Bioinformatic Analysis of Prognostic Value of SNTG2 with Immune Implications in Lung Adenocarcinoma
title_full Bioinformatic Analysis of Prognostic Value of SNTG2 with Immune Implications in Lung Adenocarcinoma
title_fullStr Bioinformatic Analysis of Prognostic Value of SNTG2 with Immune Implications in Lung Adenocarcinoma
title_full_unstemmed Bioinformatic Analysis of Prognostic Value of SNTG2 with Immune Implications in Lung Adenocarcinoma
title_short Bioinformatic Analysis of Prognostic Value of SNTG2 with Immune Implications in Lung Adenocarcinoma
title_sort bioinformatic analysis of prognostic value of sntg2 with immune implications in lung adenocarcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148212/
https://www.ncbi.nlm.nih.gov/pubmed/35637702
http://dx.doi.org/10.2147/IJGM.S355393
work_keys_str_mv AT zhoujian bioinformaticanalysisofprognosticvalueofsntg2withimmuneimplicationsinlungadenocarcinoma
AT wenyang bioinformaticanalysisofprognosticvalueofsntg2withimmuneimplicationsinlungadenocarcinoma
AT chenxiangtian bioinformaticanalysisofprognosticvalueofsntg2withimmuneimplicationsinlungadenocarcinoma
AT guolinlang bioinformaticanalysisofprognosticvalueofsntg2withimmuneimplicationsinlungadenocarcinoma